Peter Hersey is Professor of Immuno-Oncology in the University of Sydney and a faculty member of the Melanoma Institute Australia (MIA). He has extensive experience in both clinical and laboratory-based research on melanoma. His translational research activities have involved phase I-III trials of immunotherapy on melanoma, with modified peptide antigens and dendritic cell vaccines. He has taken a leading role in studies on properties of melanoma cells that make them resistant to treatment and to apoptosis. He has participated in most of the key clinical trials on immunotherapy with immune checkpoint inhibitors. He has received continuous funding from the NHMRC for his research and has been a joint holder of the prestigious NHMRC program grant since 2005 which was renewed to end of 2020. He has published over 374 peer reviewed papers on melanoma. His current interest centres on the role of epigenetic regulators in progression and treatment of melanoma.